PL1765290T3 - Stabilizowane, przesycone stałe roztwory leków steroidowych - Google Patents

Stabilizowane, przesycone stałe roztwory leków steroidowych

Info

Publication number
PL1765290T3
PL1765290T3 PL05718248T PL05718248T PL1765290T3 PL 1765290 T3 PL1765290 T3 PL 1765290T3 PL 05718248 T PL05718248 T PL 05718248T PL 05718248 T PL05718248 T PL 05718248T PL 1765290 T3 PL1765290 T3 PL 1765290T3
Authority
PL
Poland
Prior art keywords
solid solutions
supersaturated solid
steroidal drugs
stabilised
stabilised supersaturated
Prior art date
Application number
PL05718248T
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1765290(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PL1765290T3 publication Critical patent/PL1765290T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PL05718248T 2004-03-10 2005-03-10 Stabilizowane, przesycone stałe roztwory leków steroidowych PL1765290T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs
EP05718248A EP1765290B1 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
PL1765290T3 true PL1765290T3 (pl) 2010-02-26

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05718248T PL1765290T3 (pl) 2004-03-10 2005-03-10 Stabilizowane, przesycone stałe roztwory leków steroidowych

Country Status (32)

Country Link
US (1) US8715735B2 (pl)
EP (2) EP2087883B1 (pl)
JP (1) JP5006185B2 (pl)
KR (1) KR101210695B1 (pl)
CN (1) CN1984644B (pl)
AR (1) AR048500A1 (pl)
AT (1) ATE442131T1 (pl)
AU (1) AU2005221403B8 (pl)
BR (1) BRPI0507342A (pl)
CA (1) CA2558582C (pl)
CR (1) CR8630A (pl)
DE (1) DE602005016551D1 (pl)
DK (1) DK1765290T3 (pl)
EA (1) EA012746B1 (pl)
EC (1) ECSP066902A (pl)
ES (2) ES2332229T3 (pl)
GT (1) GT200500045A (pl)
HR (1) HRP20090614T1 (pl)
IL (1) IL177894A0 (pl)
MY (1) MY142989A (pl)
NO (1) NO20064473L (pl)
NZ (1) NZ549793A (pl)
PA (1) PA8626101A1 (pl)
PE (1) PE20060016A1 (pl)
PL (1) PL1765290T3 (pl)
PT (1) PT1765290E (pl)
RS (1) RS51076B (pl)
SI (1) SI1765290T1 (pl)
SV (1) SV2005002044A (pl)
TW (1) TWI345986B (pl)
UY (1) UY28803A1 (pl)
WO (1) WO2005087199A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
US20090312439A1 (en) * 2006-05-10 2009-12-17 Ralph Hofmann Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
EP4403221A3 (en) 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20100119601A1 (en) * 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
EP2249803A2 (en) * 2008-02-13 2010-11-17 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
AU2009224418B2 (en) * 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
CN103479584A (zh) 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
WO2010042930A1 (en) * 2008-10-10 2010-04-15 Ahmed Salah U Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
WO2010094623A1 (en) * 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9005608B2 (en) * 2009-03-24 2015-04-14 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CA2992923C (en) 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
AU2018222468B2 (en) * 2017-02-14 2023-05-11 Dsm Ip Assets B.V. Water dispersible formulations
CN110381747A (zh) * 2017-02-14 2019-10-25 帝斯曼知识产权资产管理有限公司 贮存稳定的配制物
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP7847966B2 (ja) * 2020-10-23 2026-04-20 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
ATE118178T1 (de) * 1990-11-29 1995-02-15 Faulding F H & Co Ltd Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern.
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
EP1598069B1 (en) 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
IL150775A0 (en) 2000-01-18 2003-02-12 Schering Ag Drospirenone for hormone replacement therapy
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
JP4547148B2 (ja) * 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CA2497838C (en) 2002-09-05 2012-07-17 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16- substituted testosterone analogues
ES2338781T3 (es) 2002-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Uso de la drospirenona para el tratamiento de una hipertension.
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
EP1601347A1 (en) * 2003-02-19 2005-12-07 LifeCycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
CA2558393A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed

Also Published As

Publication number Publication date
CN1984644A (zh) 2007-06-20
EA200601588A1 (ru) 2007-02-27
GT200500045A (es) 2005-10-31
NO20064473L (no) 2006-10-10
SV2005002044A (es) 2005-11-04
AU2005221403B2 (en) 2009-12-10
NZ549793A (en) 2010-06-25
HK1103660A1 (en) 2007-12-28
AU2005221403A1 (en) 2005-09-22
CA2558582C (en) 2013-07-16
PT1765290E (pt) 2009-11-23
PA8626101A1 (es) 2006-07-03
RS51076B (sr) 2010-10-31
WO2005087199A8 (en) 2007-03-29
MY142989A (en) 2011-02-14
TWI345986B (en) 2011-08-01
EP2087883A1 (en) 2009-08-12
CA2558582A1 (en) 2005-09-22
KR101210695B1 (ko) 2012-12-11
IL177894A0 (en) 2006-12-31
CR8630A (es) 2007-06-06
EA012746B1 (ru) 2009-12-30
EP1765290A2 (en) 2007-03-28
JP2007528389A (ja) 2007-10-11
WO2005087199A2 (en) 2005-09-22
AR048500A1 (es) 2006-05-03
BRPI0507342A (pt) 2007-07-03
TW200600116A (en) 2006-01-01
ATE442131T1 (de) 2009-09-15
PE20060016A1 (es) 2006-02-16
ES2390406T3 (es) 2012-11-12
CN1984644B (zh) 2010-12-08
JP5006185B2 (ja) 2012-08-22
DK1765290T3 (da) 2009-11-02
KR20060132999A (ko) 2006-12-22
EP1765290B1 (en) 2009-09-09
UY28803A1 (es) 2005-10-31
EP2087883B1 (en) 2012-07-25
ES2332229T3 (es) 2010-01-29
ECSP066902A (es) 2006-12-20
HRP20090614T1 (hr) 2009-12-31
US8715735B2 (en) 2014-05-06
SI1765290T1 (sl) 2010-01-29
US20050207990A1 (en) 2005-09-22
AU2005221403B8 (en) 2010-01-07
DE602005016551D1 (de) 2009-10-22
WO2005087199A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
SI1765290T1 (sl) Stabilizirane supernasičene trdne raztopine steroidnih zdravil
SI1636190T1 (sl) Stabilni kristal 4-oksokinolinske spojine
IL178874A0 (en) Preparation of nanoparticle materials
IL182633A0 (en) Pharmaceutical compositions containing a sex steroid precursor
ZA200708327B (en) Reduction of postoperative pain medication
AP2007003921A0 (en) Therapeutic uses of inhibitors of rtp801
GB0421149D0 (en) Preparation of oxycodone
IL180359A0 (en) Solid forms of linezolid and processes for preparation thereof
PT1701698E (pt) Composição farmacêutica para a administração oral de cci-779
IL176932A0 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
GB0416728D0 (en) Medicinal use of receptor ligands
EP1796676A4 (en) TRANSDERMALE ADMINISTRATION OF PHYCOTOXINES
GB0410470D0 (en) Pharmaceutical compound and polymorphs thereof
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
EP1778252A4 (en) NON-CARDIOTOXIC PHARMACEUTICAL COMPOUNDS
PL1740204T3 (pl) Lecznicze zastosowanie alfa-mannozydazy
ZA200804266B (en) Therapeutic uses of steroidal compounds
AP2006003622A0 (en) Nitrooxyderivatives of antihypertensive drugs
PL373776A1 (pl) Doustna kompozycja farmaceutyczna
TWM275831U (en) Improved structure of cinerary urn
HUE037787T2 (hu) Alfa-mannozidáz gyógyászati alkalmazása
AU2005904363A0 (en) Administration of Drugs
SI1701698T1 (sl) Neposredno stisljiv farmacevtski sestavek za peroralno dajanje CCI-779
GB0408878D0 (en) Medicinal compounds
GB0410028D0 (en) Pharmaceutical formulation of apomorphine